Moheb Nasr, PhD GlaxoSmithKline

After 22 years at FDA, Dr. Nasr joined GlaxoSmithKline (GSK) in September 2011 as Vice President for Global CMC Strategy. Dr. Nasr is responsible for the development and the execution of GSK CMC regulatory strategy. Dr. Nasr is a member of GSK leadership and governance boards accountable for product development, manufacturing and supply, and regulatory oversight.

Prior to joining GSK, Dr. Nasr served as the Director of the Office of New Drug Quality Assessment (ONDQA), CDER, FDA. Dr. Nasr established and led ONDQA for 8 years. Dr. Nasr represented FDA at ICH and was instrumental in the development of QbD concept and several regulatory guidelines.

Dr. Nasr obtained his Ph.D. degree in Chemistry at the University of Minnesota in Minneapolis, USA. Dr. Nasr is an elected Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the recipient of AAPS Regulatory Science Achievement Award, and University of Wisconsin Pharmaceutical Analysis Excellence Award.